Shared and distinct mechanisms of iron acquisition by bacterial and fungal pathogens of humans
M Caza, JW Kronstad - Frontiers in cellular and infection microbiology, 2013 - frontiersin.org
Iron is the most abundant transition metal in the human body and its bioavailability is
stringently controlled. In particular, iron is tightly bound to host proteins such as transferrin to …
stringently controlled. In particular, iron is tightly bound to host proteins such as transferrin to …
Mycobacteria, metals, and the macrophage
O Neyrolles, F Wolschendorf, A Mitra… - Immunological …, 2015 - Wiley Online Library
Mycobacterium tuberculosis is a facultative intracellular pathogen that thrives inside host
macrophages. A key trait of M. tuberculosis is to exploit and manipulate metal cation …
macrophages. A key trait of M. tuberculosis is to exploit and manipulate metal cation …
Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis
Nitric oxide contributes to protection from tuberculosis. It is generally assumed that this
protection is due to direct inhibition of Mycobacterium tuberculosis growth, which prevents …
protection is due to direct inhibition of Mycobacterium tuberculosis growth, which prevents …
Multitarget drug discovery for tuberculosis and other infectious diseases
K Li, LA Schurig-Briccio, X Feng… - Journal of medicinal …, 2014 - ACS Publications
We report the discovery of a series of new drug leads that have potent activity against
Mycobacterium tuberculosis as well as against other bacteria, fungi, and a malaria parasite …
Mycobacterium tuberculosis as well as against other bacteria, fungi, and a malaria parasite …
Structural and functional diversity of resistance–nodulation–cell division transporters
Multidrug resistant (MDR) bacteria are a global threat with many common infections
becoming increasingly difficult to eliminate. While significant effort has gone into the …
becoming increasingly difficult to eliminate. While significant effort has gone into the …
Iron Acquisition in Mycobacterium tuberculosis
The highly contagious disease tuberculosis (TB) is caused by the bacterium Mycobacterium
tuberculosis (Mtb), which has been evolving drug resistance at an alarming rate. Like all …
tuberculosis (Mtb), which has been evolving drug resistance at an alarming rate. Like all …
Recent advancements in the development of anti-tuberculosis drugs
S Chetty, M Ramesh, A Singh-Pillay… - Bioorganic & medicinal …, 2017 - Elsevier
Modern chemotherapy has significantly improved patient outcomes against drug-sensitive
tuberculosis. However, the rapid emergence of drug-resistant tuberculosis, together with the …
tuberculosis. However, the rapid emergence of drug-resistant tuberculosis, together with the …
Indole-2-carboxamide-based MmpL3 inhibitors show exceptional antitubercular activity in an animal model of tuberculosis infection
J Stec, OK Onajole, S Lun, H Guo… - Journal of medicinal …, 2016 - ACS Publications
Our team had previously identified certain indolecarboxamides that represented a new
chemical scaffold that showed promising anti-TB activity at both an in vitro and in vivo level …
chemical scaffold that showed promising anti-TB activity at both an in vitro and in vivo level …
The tuberculosis drug discovery and development pipeline and emerging drug targets
K Mdluli, T Kaneko, A Upton - Cold Spring …, 2015 - perspectivesinmedicine.cshlp.org
The recent accelerated approval for use in extensively drug-resistant and multidrug-resistant-
tuberculosis (MDR-TB) of two first-in-class TB drugs, bedaquiline and delamanid, has …
tuberculosis (MDR-TB) of two first-in-class TB drugs, bedaquiline and delamanid, has …
High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds
M Zampieri, B Szappanos, MV Buchieri… - Science translational …, 2018 - science.org
Rapidly spreading antibiotic resistance and the low discovery rate of new antimicrobial
compounds demand more effective strategies for early drug discovery. One bottleneck in the …
compounds demand more effective strategies for early drug discovery. One bottleneck in the …